Platelets

Papers
(The TQCC of Platelets is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation68
Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention43
Enhanced platelet sensitization is accompanied by increased expression of the transporter MRP4 and elevated plasma S1P levels in mild COVID-19 convalescents34
Apoptosis is one cause of thrombocytopenia in patients with high-altitude polycythemia33
Development of an automated chemiluminescence enzyme immunoassay for the measurement of soluble C-type lectin-like receptor 2 (sCLEC-2) and molecular forms of sCLEC-2 measured in patient plasma32
Contributing role of mitochondrial energy metabolism on platelet adhesion, activation and thrombus formation under blood flow conditions31
Platelet-derived microparticles stimulated by anti-β 2 GPI/β 2 GPI complexes induce pyroptosis of endothelial cells in antiphospho29
How can we use proteomics to learn more about platelets?26
Trends among platelet function, arterial calcium, and vascular function measures23
The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis22
Platelets and open access – a new era dawns21
Sex-specific relationship between blood selenium levels and platelet count in a large cohort representative of the United States population19
Clinical features and treatment effect of HIV-associated immune thrombocytopenia—single center Ten-Years data summary19
The natural anticoagulant protein S; hemostatic functions and deficiency17
Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial16
Chronic immune thrombocytopenia in a child with X-linked agammaglobulinemia-an uncommon phenotype16
Increased circulating platelet-derived extracellular vesicles in severe COVID-19 disease16
Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients16
Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis16
Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia16
Extracellular thiol isomerase ERp5 regulates integrin αIIbβ3 activation by inhibition of fibrinogen binding15
Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study15
Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF14
Phosphorylation of (Ser 291) in the linker insert of Syk negatively regulates ITAM signaling in platelets14
Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength13
Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation13
Variation in activation marker expression within the platelet population – a new parameter for evaluation of platelet flow cytometry data13
Inflammation modifies the platelet reactivity among thrombocytopenia patients undergoing percutaneous coronary intervention12
European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia12
Circulating microRNAs as biomarkers and mediators of platelet activation12
Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure12
Identification of UDP-Glucuronosyltransferase mRNA in human platelets: differential levels in smokers and non-smokers11
In memory of Dr. Susan S. Smyth, MD/Ph.D.11
Role of platelet count in a murine stasis model of deep vein thrombosis11
Neurosurgical bleeding in platelet storage pool disorder: a case report11
Recent advances in microfluidic technology of arterial thrombosis investigations11
A splice mutation in RASGRP2 gene in the patient with recurrent epistaxis and nasal vascular malformation11
Association of thromboxane generation with the bleeding events in aspirin users11
Impact of thrombocytopenia-associated c.-118C>T and c.-140C>G ANKRD26 5’UTR variants in three-generational pedigree11
Deep learning, 3D ultrastructural analysis reveals quantitative differences in platelet and organelle packing in COVID-19/SARSCoV2 patient-derived platelets11
Higher body mass index raises immature platelet count: potential contribution to obesity-related thrombosis11
The effect of testosterone on platelet activation and inflammation in transgender men11
Early recognition of sepsis-induced coagulopathy using the C2PAC index: a ratio of soluble type C lectin-like receptor 2 (sCLEC-2) level and platelet count10
Multiple myeloma and its treatment contribute to increased platelet reactivity10
What can we learn from senescent platelets, their transcriptomes and proteomes?10
miR-28-5p targeted Rap1b attenuates splenic inflammation infiltration in immune thrombocytopenia10
Evaluation of human platelet granules by structured illumination laser fluorescence microscopy10
The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention10
Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology10
Application of the Cellular Thermal Shift Assay (CETSA) to validate drug target engagement in platelets10
Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective10
Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study10
Factors influencing platelet isolation: a prospective multicenter study from Western China10
Cardiometabolic risk factor burden associates with an immature platelet profile10
Congenital thrombocytopenia associated with a heterozygous variant in the MEIS1 gene encoding a transcription factor essential for megakaryopoiesis9
In vitro evaluation of platelet extracellular vesicles (PEVs) for corneal endothelial regeneration9
Deficiency of BLOS1 moderately impairs the biogenesis of platelet dense granules9
Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia9
Q94 is not a selective modulator of proteinase-activated receptor 1 (PAR1) in platelets9
Evaluating stored platelet shape change using imaging flow cytometry9
Appraising non-linear association between pre-diagnostic platelet counts and cancer survival outcomes: observational and genetic analysis9
Platelet-derived respiratory-competent mitochondria transfer to mesenchymal stem cells to promote wound healing via metabolic reprogramming9
Age and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: a post hoc analysis of the randomized PATH-PCI trial9
Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies9
Comparison of in-hospital net clinical outcomes of ticagrelor and clopidogrel in acute coronary syndrome patients stratified by CRUSADE score: findings from the CCC-ACS registry9
Cryopreservation affects platelet macromolecular composition over time after thawing and differently impacts on cancer cells behavior in vitro8
Association between endometriosis, infertility and autoimmune antiplatelet glycoprotein VI antibodies in two patients8
From reticulated platelets to immature platelet fraction: structure, function, and clinical applications8
Rapid isolation of mature murine primary megakaryocytes by size exclusion via filtration8
Alantolactone induces platelet apoptosis by activating the Akt pathway8
Platelet counts in HFE p.C282Y/p.C282Y and wt/wt post-screening clinical evaluation participants8
Roles of non-coding RNA in megakaryocytopoiesis and thrombopoiesis: new target therapies in ITP8
Platelet index on admission as a predictor of bacteremia in acute cholangitis: a 7-year retrospective observational study8
Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors8
A novel, quantitative clot retraction assay to evaluate platelet function8
New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans8
0.033514976501465